UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds ...

Exxon Mobil leads fresh analyst reports as Permian and Guyana output power growth, while Palantir's AI platforms and AstraZeneca's drug pipeline highlight key momentum.

AstraZeneca's share price looks anchored to an outdated story — and the latest results suggest the market may be missing something. The post Below £151, here’s why AstraZeneca’s share price looks a ...

AstraZeneca’s latest update covers ALAFOSS-01, a first-in-human Phase I/IIa trial of AZD0022 in adults with advanced cancers carrying a KRASG12D mutation. The study aimed to test safety, dosing, and ...

AstraZeneca expects continued sales growth this year and restated its ambitious 2030 revenue target of $80 billion as it posted a surge in emerging-market results. The British drugmaker said it ...

AstraZeneca said revenue grew in the third quarter, boosted by the strength of the pharmaceutical giant's treatments pipeline. The U.K. company booked a 14% on-year increase in third-quarter core ...

AstraZeneca’s latest fair value estimate has been set at £162.67, up from £152.79, marking a modest uplift in the central value per share that many investors track closely. That shift lines up with ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca PLC (AZN), RTX Corp. (RTX ...

AstraZeneca's revenue grew in the third quarter, boosted by the strength of the company's treatments pipeline. "We are...delivering on our strategy to strengthen our operations in the United States to ...